Kidney Testing Gets Under the Skin
A microneedle platform captured a kidney injury biomarker from interstitial fluid
Clinical Scorecard: Kidney Testing Gets Under the Skin
At a Glance
| Category | Detail |
|---|
| Condition | Kidney Injury Biomarker Detection |
| Key Mechanisms | Detection of neutrophil gelatinase-associated lipocalin in dermal interstitial fluid. |
| Target Population | Individuals with potential kidney injury. |
| Care Setting | Minimally invasive biomarker testing. |
Key Highlights
- Microneedle patch measures kidney injury biomarker in interstitial fluid.
- Neutrophil gelatinase-associated lipocalin increases before conventional markers.
- Patch remains functional after high-temperature exposure.
- Detection limits: 9 pg/mL in humans, 16 pg/mL in mice.
- Study highlights need for sample-specific reference ranges.
Guideline-Based Recommendations
Diagnosis
- Further studies needed to define clinically actionable interstitial fluid thresholds.
- Assess diagnostic performance in patients.
Management
- Multiplexed measurement of additional kidney biomarkers may improve specificity.
Monitoring & Follow-up
- Monitor interstitial fluid neutrophil gelatinase-associated lipocalin levels.
Risks
- Concentration affected by inflammation and other conditions.
Patient & Prescribing Data
Not tested in patients with kidney disease.
Potential for minimally invasive testing in kidney injury detection.
Clinical Best Practices
- Consider interstitial fluid as an alternative matrix for kidney biomarker testing.
- Ensure proper calibration and imaging post-patch removal.
Related Resources & Content
